Researchers have claimed that a compound which was developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease.
"Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer's disease," said Mohamed Naguib, M.D., Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine.
"Development of this compound as a potential drug for Alzheimer's would take many more years, but this is a promising finding worthy of further investigation."
In the study, the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer's disease.
Treatment with the compound restored cognition, memory and synaptic plasticity - a key neurological foundation of learning and memory - in an animal model.
The study has been published online in the Neurobiology of Aging.